Ligand Pharmaceuticals LGND Vaxneuvance — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's vaxneuvance — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's vaxneuvance — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported vaxneuvance — total revenues and income of $1.61M in Q1 2026.
- How has Ligand Pharmaceuticals's vaxneuvance — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's vaxneuvance — total revenues and income increased by 25.3% year-over-year, from $1.29M to $1.61M.
- What is the long-term trend for Ligand Pharmaceuticals's vaxneuvance — total revenues and income?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's vaxneuvance — total revenues and income has grown at a 89.8% compound annual growth rate (CAGR), from $1.08M to $7.4M.
- What does vaxneuvance — total revenues and income mean?
- This metric represents the aggregate financial inflows generated by the Vaxneuvance product line, including royalties, milestone payments, and licensing fees. It serves as a key indicator of the commercial performance and market adoption of this specific pharmaceutical asset within the company's broader portfolio. Monitoring this revenue stream helps investors assess the contribution of individual licensed products to the company's overall top-line growth and long-term value creation.